Acrylamide compounds and use thereof for inhibiting apoptosis
US-9199978-B2 · Dec 1, 2015 · US
Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
US9555024B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9555024-B2 |
| Application number | US-201514623370-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 16, 2015 |
| Priority date | Aug 15, 2011 |
| Publication date | Jan 31, 2017 |
| Grant date | Jan 31, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In one aspect, the invention relates to substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of lysine-specific histone demethylase, including LSD1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the LSD1. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for the treatment of cancer in a mammal, wherein the cancer is selected from uterine, breast, colon, pancreas, prostate or brain cancer, comprising the step of administering to the mammal an effective amount of a compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63) · CPC title
Antineoplastic agents · CPC title
- A61K31/4453Primary
only substituted in position 1, e.g. propipocaine, diperodon · CPC title
with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings · CPC title
having four-membered rings, e.g. azetidine · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9555024B2 cover?
- In one aspect, the invention relates to substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of lysine-specific histone demethylase, including LSD1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat diso…
- Who is the assignee on this patent?
- Univ Utah Res Found
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4453. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).